IS7654A - Notkun MGLUR5 mótlyfja til meðhöndlunar á maga-vélindis-bakflæðissjúkdómum - Google Patents

Notkun MGLUR5 mótlyfja til meðhöndlunar á maga-vélindis-bakflæðissjúkdómum

Info

Publication number
IS7654A
IS7654A IS7654A IS7654A IS7654A IS 7654 A IS7654 A IS 7654A IS 7654 A IS7654 A IS 7654A IS 7654 A IS7654 A IS 7654A IS 7654 A IS7654 A IS 7654A
Authority
IS
Iceland
Prior art keywords
treatment
gastro
reflux disease
oesophageal reflux
antagonists
Prior art date
Application number
IS7654A
Other languages
English (en)
Inventor
Lehmann Anders
Mattsson Jan
M. Stormann Thomas
Original Assignee
Astrazeneca Ab
Nps Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20288301&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS7654(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, Nps Pharmaceuticals, Inc. filed Critical Astrazeneca Ab
Publication of IS7654A publication Critical patent/IS7654A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
IS7654A 2002-06-20 2005-01-19 Notkun MGLUR5 mótlyfja til meðhöndlunar á maga-vélindis-bakflæðissjúkdómum IS7654A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0201943A SE0201943D0 (sv) 2002-06-20 2002-06-20 New use
PCT/US2003/016223 WO2004000316A1 (en) 2002-06-20 2003-06-19 Use of mglur5 antagonists for the treatment of gerd

Publications (1)

Publication Number Publication Date
IS7654A true IS7654A (is) 2005-01-19

Family

ID=20288301

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7654A IS7654A (is) 2002-06-20 2005-01-19 Notkun MGLUR5 mótlyfja til meðhöndlunar á maga-vélindis-bakflæðissjúkdómum

Country Status (25)

Country Link
EP (1) EP1513525B1 (is)
JP (2) JP4683920B2 (is)
CN (1) CN100430056C (is)
AT (1) ATE395059T1 (is)
AU (1) AU2003241585B2 (is)
BR (1) BR0311759A (is)
CA (1) CA2489730C (is)
CY (1) CY1107954T1 (is)
DE (1) DE60320990D1 (is)
DK (1) DK1513525T3 (is)
ES (1) ES2304510T3 (is)
HK (1) HK1075833A1 (is)
IL (1) IL165138A0 (is)
IS (1) IS7654A (is)
MX (1) MXPA04012659A (is)
NO (1) NO20050154L (is)
NZ (1) NZ536559A (is)
PL (1) PL372186A1 (is)
PT (1) PT1513525E (is)
RU (1) RU2324484C2 (is)
SE (1) SE0201943D0 (is)
SI (1) SI1513525T1 (is)
UA (1) UA81627C2 (is)
WO (1) WO2004000316A1 (is)
ZA (1) ZA200409908B (is)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964609B2 (en) 2002-06-20 2011-06-21 Astrazeneca Ab Use of mGluR5 antagonists for the treatment of gerd
SE0303418D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 1
WO2005060971A1 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of reflux-related diseases
WO2005060961A2 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
WO2005077368A2 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
WO2005077345A1 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
KR20070026382A (ko) * 2004-02-18 2007-03-08 아스트라제네카 아베 아세틸린성 피페라진 화합물 및 대사성 글루타메이트수용체 길항제로서 이들의 용도
UA82434C2 (uk) * 2004-02-18 2008-04-10 Astrazeneca Ab Полігетероциклічні сполуки і їх застосування як антагоністів метаботропного рецептора глютамату, фармацевтична композиція на їх основі
GB0514296D0 (en) * 2005-07-12 2005-08-17 Novartis Ag Organic compounds
PL2001849T3 (pl) * 2006-03-29 2015-04-30 Hoffmann La Roche Pochodne pirydyny i pirymidyny jako antagoniści mGluR2
JP2010502664A (ja) 2006-09-11 2010-01-28 ノバルティス アクチエンゲゼルシャフト 代謝型グルタミン酸受容体の調節剤としてのニコチン酸誘導体
JP2008245225A (ja) * 2007-03-29 2008-10-09 Kddi Corp 波長パス経路決定装置、波長パス設定制御システム及びプログラム
WO2009024491A1 (en) * 2007-08-20 2009-02-26 F. Hoffmann-La Roche Ag Use of mglur5 antagonists for the treatment of gerd
BRPI0913642A2 (pt) 2008-06-30 2015-11-24 Novartis Ag produtos de combinação
EP2959902A1 (en) 2009-07-23 2015-12-30 Novartis AG Use of azabicycloalkyl derivatives for the treatment or prevention of ataxia
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
WO2011048150A1 (en) 2009-10-20 2011-04-28 Novartis Ag Use of 1h-quinazoline-2,4-diones
BR112012033290A2 (pt) 2010-06-24 2016-11-22 Novartis Ag uso de 1h-quinazolina-2,4-dionas
CN103442701A (zh) 2011-01-27 2013-12-11 诺瓦提斯公司 烟碱乙酰胆碱受体α7激活剂的用途
CA2846503A1 (en) 2011-09-07 2013-03-14 Novartis Ag Use of 1h-quinazoline-2,4-diones for use in the prevention or treatment of photosensitive epilepsy
BR112015016994A8 (pt) 2013-01-15 2018-01-23 Novartis Ag uso de agonistas do receptor alfa 7 nicotínico de acetilcolina
CA2898045C (en) 2013-01-15 2018-08-28 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0250572A1 (en) * 1986-01-03 1988-01-07 The University Of Melbourne Gastro-oesophageal reflux composition
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
CA2332774A1 (en) * 1998-05-15 1999-11-25 Dov Michaeli Method for the treatment of gastroesophageal reflux disease
CZ2002599A3 (cs) * 1999-08-19 2002-06-12 Nps Pharmaceuticals Inc. Heteropolycyklické sloučeniny a jejich pouľití jako antagonistů metabotropního receptoru glutamátu

Also Published As

Publication number Publication date
JP4683920B2 (ja) 2011-05-18
ZA200409908B (en) 2006-08-30
SE0201943D0 (sv) 2002-06-20
DK1513525T3 (da) 2008-08-11
PT1513525E (pt) 2008-06-24
ATE395059T1 (de) 2008-05-15
EP1513525B1 (en) 2008-05-14
UA81627C2 (ru) 2008-01-25
CA2489730A1 (en) 2003-12-31
CA2489730C (en) 2011-11-22
AU2003241585A1 (en) 2004-01-06
WO2004000316A1 (en) 2003-12-31
PL372186A1 (en) 2005-07-11
BR0311759A (pt) 2005-03-08
EP1513525A1 (en) 2005-03-16
HK1075833A1 (en) 2005-12-30
DE60320990D1 (de) 2008-06-26
IL165138A0 (en) 2005-12-18
SI1513525T1 (sl) 2008-08-31
CN1662235A (zh) 2005-08-31
JP2011068669A (ja) 2011-04-07
CY1107954T1 (el) 2013-09-04
ES2304510T3 (es) 2008-10-16
RU2324484C2 (ru) 2008-05-20
JP2006507225A (ja) 2006-03-02
AU2003241585B2 (en) 2009-06-25
CN100430056C (zh) 2008-11-05
MXPA04012659A (es) 2006-05-25
NO20050154L (no) 2005-01-11
NZ536559A (en) 2007-08-31
RU2005101411A (ru) 2005-07-10

Similar Documents

Publication Publication Date Title
IS7654A (is) Notkun MGLUR5 mótlyfja til meðhöndlunar á maga-vélindis-bakflæðissjúkdómum
DK1723144T3 (da) Yderligere heteropolycykliske forbindelser og anvendelse deraf som metabotropiske glutamareceptor-antagonister
DE69820632D1 (de) 2-phenyl-substituierte 1-(n-phenylaminoalkyl)-piperazin-derivate
DE60205481D1 (de) Furan and thiophen derivate die menschliche peroxisome proliferator aktivierte receptoren aktivieren
NO20035367D0 (no) Modulatorer av peroksisomproliferatoraktiverte reseptorer (PPAR)
WO2005077373A3 (en) Treatment of gastro-esophageal reflux disease (gerd)
WO2005077368A3 (en) Treatment of gastro-esophageal reflux disease (gerd)
CY1110863T1 (el) Παραγωγα του 2-(8,9-διοξο-2,6-διαζαδικυκλο (5.2.0)-εννε-1(7)-εν-2-υλ)αλκυλ-φωσφονικου οξεος και η χρηση τους ως ανταγωνιστων του ν-μεθυλ- d-ασπαρτικου (nmda) υποδοχεα
IS6617A (is) Melanókortín viðtakabindlar
ITMI20021620A1 (it) Composto ad ativita' antitumorale
EA200701181A1 (ru) Лекарственные средства, предназначенные для лечения или предупреждения фиброзных заболеваний
EA200700997A1 (ru) 2,5- и 2,6-дизамещенные аналоги бензазола, полезные в качестве ингибиторов протеинкиназ
EA200301143A1 (ru) Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6
ATE399164T1 (de) Antagonisten des opioidrezeptors
NO20075209L (no) Substituerte aryl 1,4-pyrazinderivater
ATE399175T1 (de) Hemmstoffe der urokinase, ihre herstellung und verwendung
DE60207104D1 (de) 2-amino-4-heteroarylethyl-thiazolinderivate und ihre verwendung als hemmstoffe der induzierbaren no-synthase
WO2003043619A8 (en) New use for the treatment of gastroesophageal reflux disease
RS100104A (en) 1,3-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
SE0201939D0 (sv) New combination
PE20020052A1 (es) Derivados de sulfonamidas util para potenciar la funcion del receptor de glutamato
SE0303491D0 (sv) New use VI
SE0303492D0 (sv) New use VII
SE0303490D0 (sv) New use V
DE69922918D1 (de) Neuropeptid Y Antagonisten